Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLPT ClearPoint Neuro	$12.09 -3.6%	$12.72	$5.11 ▼ $19.22	$338.39M	1.03	234,185 shs	175,591 shs
LUCD Lucid Diagnostics	$1.52	$1.35	$0.68 ▼ $1.80	$164.45M	1.28	534,651 shs	1.07 million shs
NPCE NeuroPace	$12.46 -1.6%	$12.80	$5.45 ▼ $18.98	$408.68M	2.04	156,952 shs	761,185 shs
TMCI Treace Medical Concepts	$5.85 -3.9%	$7.09	$4.54 ▼ $10.79	$367.91M	0.79	605,542 shs	773,287 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLPT ClearPoint Neuro	-3.59%	-0.58%	-17.81%	-14.86%	+119.42%
LUCD Lucid Diagnostics	0.00%	+14.29%	+18.75%	+1.33%	+68.46%
NPCE NeuroPace	-1.58%	-31.27%	+7.23%	-0.80%	+75.74%
TMCI Treace Medical Concepts	-3.94%	-7.00%	-15.22%	-35.93%	+15.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLPT ClearPoint Neuro	1.819 of 5 stars	3.5	2.0	2.6	0.0	0.6
LUCD Lucid Diagnostics	2.7402 of 5 stars	3.6	3.0	3.0	1.7	0.6
NPCE NeuroPace	2.3368 of 5 stars	2.4	3.0	2.5	4.2	0.6
TMCI Treace Medical Concepts	2.3029 of 5 stars	3.1	1.0	2.3	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLPT ClearPoint Neuro	3.00	Buy	$25.00	106.78% Upside
LUCD Lucid Diagnostics	3.20	Buy	$3.50	130.26% Upside
NPCE NeuroPace	2.83	Moderate Buy	$15.50	24.40% Upside
TMCI Treace Medical Concepts	2.29	Hold	$10.16	73.63% Upside

Current Analyst Ratings Breakdown

Latest LUCD, TMCI, NPCE, and CLPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	NPCE NeuroPace	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
5/15/2025	LUCD Lucid Diagnostics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.00 ➝ $2.00
5/14/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
5/14/2025	NPCE NeuroPace	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $16.00
5/14/2025	NPCE NeuroPace	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$17.00 ➝ $17.00
5/9/2025	TMCI Treace Medical Concepts	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $8.60
4/21/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.50
4/11/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
4/11/2025	TMCI Treace Medical Concepts	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$9.50 ➝ $8.00
4/1/2025	CLPT ClearPoint Neuro	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$19.00 ➝ $25.00
3/26/2025	LUCD Lucid Diagnostics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.00 ➝ $2.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLPT ClearPoint Neuro	$32.24M	10.50	N/A	N/A	$0.86 per share	14.06
LUCD Lucid Diagnostics	$4.17M	39.41	N/A	N/A	($0.47) per share	-3.23
NPCE NeuroPace	$84.31M	4.85	N/A	N/A	$0.79 per share	15.77
TMCI Treace Medical Concepts	$210.82M	1.75	N/A	N/A	$2.24 per share	2.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLPT ClearPoint Neuro	-$22.09M	-$0.76	N/A	N/A	N/A	-59.64%	-62.10%	-38.39%	8/6/2025 (Estimated)
LUCD Lucid Diagnostics	-$52.67M	-$1.34	N/A	N/A	N/A	-1,069.87%	N/A	-123.54%	8/11/2025 (Estimated)
NPCE NeuroPace	-$32.96M	-$0.84	N/A	N/A	N/A	-36.74%	-205.41%	-28.29%	8/12/2025 (Estimated)
TMCI Treace Medical Concepts	-$49.53M	-$0.85	N/A	N/A	N/A	-30.33%	-51.12%	-26.36%	8/5/2025 (Estimated)

Latest LUCD, TMCI, NPCE, and CLPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CLPT ClearPoint Neuro	-$0.15	-$0.22	-$0.07	-$0.22	$8.21 million	$8.49 million
5/13/2025	Q1 2025	NPCE NeuroPace	-$0.26	-$0.21	+$0.05	-$0.21	$21.85 million	$22.52 million
5/8/2025	Q1 2025	TMCI Treace Medical Concepts	-$0.31	-$0.25	+$0.06	-$0.25	$52.07 million	$52.57 million
3/4/2025	Q4 2024	NPCE NeuroPace	-$0.25	-$0.18	+$0.07	-$0.18	$21.14 million	$21.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLPT ClearPoint Neuro	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
NPCE NeuroPace	N/A	N/A	N/A	N/A	N/A
TMCI Treace Medical Concepts	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLPT ClearPoint Neuro	N/A	4.54	3.61
LUCD Lucid Diagnostics	N/A	1.18	1.14
NPCE NeuroPace	6.03	5.59	4.77
TMCI Treace Medical Concepts	0.51	4.12	2.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLPT ClearPoint Neuro	30.08%
LUCD Lucid Diagnostics	74.01%
NPCE NeuroPace	78.83%
TMCI Treace Medical Concepts	84.08%

Insider Ownership

Company	Insider Ownership
CLPT ClearPoint Neuro	6.97%
LUCD Lucid Diagnostics	6.80%
NPCE NeuroPace	22.20%
TMCI Treace Medical Concepts	27.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLPT ClearPoint Neuro	110	27.99 million	25.90 million	Optionable
LUCD Lucid Diagnostics	70	108.19 million	54.12 million	No Data
NPCE NeuroPace	170	32.80 million	23.22 million	Optionable
TMCI Treace Medical Concepts	250	62.89 million	47.08 million	Optionable

LUCD, TMCI, NPCE, and CLPT Headlines

Recent News About These Companies

The Gross Law Firm Notifies Treace Medical Concepts, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - TMCI

May 29 at 5:45 AM | prnewswire.com

Investor Alert: Deadline Approaching to Join Treace Medical Concepts, Inc. (TMCI) Class Action – Contact Levi & Korsinsky

May 28 at 4:30 PM | accessnewswire.com

Class Action Filed Against Treace Medical Concepts, Inc. (TMCI) Over Securities Violations - Contact Levi & Korsinsky Today

May 28 at 2:45 PM | accessnewswire.com

TMCI DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Treace Medical Concepts, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action – TMCI

May 28 at 2:23 PM | globenewswire.com

Levi & Korsinsky Notifies Treace Medical Concepts, Inc. (TMCI) Shareholders of Class Action Lawsuit and June 10, 2025 Deadline

May 28 at 12:15 PM | accessnewswire.com

Treace Medical Concepts, Inc. (TMCI) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

May 28 at 12:00 PM | prnewswire.com

Shareholders of Treace Medical Concepts, Inc. (TMCI): Protect Your Rights Before June 10, 2025 - Contact Levi & Korsinsky

May 28 at 10:45 AM | accessnewswire.com

Recover Investment Losses: Levi & Korsinsky Files Class Action Against Treace Medical Concepts, Inc. (TMCI)

May 28 at 7:15 AM | accessnewswire.com

TMCI SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Treace Medical Concepts, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

May 28 at 7:00 AM | accessnewswire.com

TMCI LAWSUIT ALERT: Levi & Korsinsky Notifies Treace Medical Concepts, Inc. Investors - Lead Plaintiff Deadline June 10, 2025

May 27 at 4:30 PM | accessnewswire.com

ROSEN, A LEADING LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TMCI

May 27 at 4:12 PM | markets.businessinsider.com

Class Action Alert: Levi & Korsinsky Reminds Treace Medical Concepts, Inc. (TMCI) Investors of June 10, 2025 Deadline

May 27 at 2:40 PM | accessnewswire.com

ROSEN, A LEADING LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TMCI

May 27 at 2:23 PM | accessnewswire.com

Investors Urged to Contact Levi & Korsinsky for Information Before June 10, 2025 - Treace Medical Concepts, Inc. (TMCI)

May 27 at 12:30 PM | accessnewswire.com

TMCI ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Treace Medical Concepts, Inc. - June 10, 2025 Deadline

May 27 at 11:00 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Treace Medical Concepts, Inc of Class Action Lawsuit and Upcoming Deadlines - TMCI

May 27 at 10:45 AM | accessnewswire.com

Treace Medical Concepts, Inc. (TMCI) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of June 10, 2025 Deadline

May 27 at 9:30 AM | accessnewswire.com

Securities Lawsuit Alert: Treace Medical Concepts, Inc. (TMCI) - Contact Levi & Korsinsky Before June 10, 2025

May 27 at 8:45 AM | accessnewswire.com

TREACE MEDICAL CONCEPTS, INC. (NASDAQ: TMCI) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Treace Medical Concepts, Inc. Investors of Upcoming Deadline

May 27 at 8:30 AM | globenewswire.com

Investor Alert: Deadline Approaching to Join Treace Medical Concepts, Inc. (TMCI) Class Action - Contact Levi & Korsinsky

May 27 at 7:25 AM | accessnewswire.com

BNP Paribas Financial Markets Makes New $590,000 Investment in Treace Medical Concepts, Inc. (NASDAQ:TMCI)

May 26 at 3:21 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD, TMCI, NPCE, and CLPT Company Descriptions

ClearPoint Neuro NASDAQ:CLPT

$12.09 -0.45 (-3.59%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$12.20 +0.12 (+0.95%)

As of 06:27 AM Eastern

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Lucid Diagnostics NASDAQ:LUCD

$1.52 0.00 (0.00%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$1.52 -0.01 (-0.33%)

As of 05:11 AM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

NeuroPace NASDAQ:NPCE

$12.46 -0.20 (-1.58%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$12.38 -0.09 (-0.68%)

As of 06:13 AM Eastern

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Treace Medical Concepts NASDAQ:TMCI

$5.85 -0.24 (-3.94%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$5.85 0.00 (0.00%)

As of 05/28/2025 04:04 PM Eastern

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time